Workshop: Commercializing a Novel Therapeutic Target for Alzheimer’s Disease
Saturday, July 25, 2020
1 – 5 p.m.
Academic scientists have an important and growing role in the translation of novel targets into potential therapeutics, a vital step in the quest to develop effective therapeutics for Alzheimer’s disease. This workshop will address key challenges academic scientists face when attempting to commercialize their science: from identifying when science is ready for translation to overcoming key challenges involved in becoming an entrepreneur starting a new company (NewCo). Some scientists don’t want to become entrepreneurs per se but still need to understand how to de-risk an idea to attract external investment, as well as the different paths to commercialization. Considerations for licensing to an existing company versus building a NewCo will be discussed.
Much of the workshop will focus on key considerations and challenges when pursuing the path towards building a NewCo. Panelists will outline ten important challenges facing inexperienced entrepreneurs and illustrate these challenges with concrete examples from their direct experiences as biotech venture investors. The session will focus on:
The workshop will include an introduction to the relevant nomenclature associated with entrepreneurship and draw important distinctions between the roles of angel investors, professional venture capitalists, philanthropic foundations, and other sources of startup funding. It will also focus on issues including:
Tracy Saxton, Ph.D., Managing Director, Dolby Family Ventures
Workshops come with separate registration fees in addition to AAIC full conference registration. Workshops can also be purchased as stand-alone events. Visit the Registration page.
Go beyond the conference — network and collaborate year-round with a global community of leaders who are working to advance Alzheimer’s and dementia research.